Thought Leadership
Exploring the COVID-19 Vaccine IP Waiver Proposal at the WTO
March 15, 2021
Allie Nawrat
Pharmaceutical Technology

Axinn partner David Silverstein was quoted in the Pharmaceutical Technology article, "Exploring the COVID-19 Vaccine IP Waiver Proposal at the WTO."

Click here to access the article. 

By using the Axinn, Veltrop & Harkrider LLP website with cookies enabled on your browser, you agree to our use of cookies during your browsing experience. Learn more about our privacy policy.